School of Pharmaceutical Sciences, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, and Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education) , Tsinghua University , Beijing 100084 , P.R. China.
Chemical and Pharmaceutical Development, Research and Development , Bayer AG , 42096 Elberfeld , Germany.
Mol Pharm. 2019 Jan 7;16(1):205-213. doi: 10.1021/acs.molpharmaceut.8b00947. Epub 2018 Nov 30.
We investigated the drug-polymer interactions in nonaqueous and aqueous environments between a poorly water-soluble drug, BAY1161909 (909), and two commonly used polymers in amorphous solid dispersions, i.e., PVP and HPMC-AS. In an nonaqueous state, with a drug-polymer Flory-Huggins interaction parameter, solution NMR and FT-IR results revealed that strong specific interactions existed between 909 and PVP, while not between 909 and HPMC-AS. After prolonged moisture exposure under 95% RH, 909/PVP intermolecular interaction no longer existed, while hydrophobic interaction between 909 and HPMC-AS occurred and persisted. In an aqueous supersaturation study of 909, codissolved PVP significantly outperformed predissolved PVP in maintaining 909 supersaturation. We hypothesized that the codissolved PVP formed a specific interaction with 909, and thus, it was able to prolong 909 supersaturation before disruption of the interaction in aqueous medium, while predissolved PVP formed hydrogen bonds with water, and thus, it was no longer able to form specific interactions with 909 to prolong its supersaturation. In contrast, HPMC-AS effectively mediated 909 supersaturation through hydrophobic interaction, which became pronounced in an aqueous environment and was independent of how HPMC-AS was added. This hypothesis was supported by dynamic light scattering analysis, wherein the formation of nanosized drug/polymer aggregations was found to be correlating with the supersaturation of 909. In summary, we concluded that polymer-mediated drug supersaturation was controlled by drug-polymer interactions persisting in an aqueous environment. Therefore, the physical nature of the drug-polymer interaction as well as the dissolution kinetic of the drug and polymer are all critically important to achieve an optimal ASD formulation design.
我们研究了在非水和水两种环境中,一种难溶性药物 BAY1161909(909)与两种常用于无定形固体分散体的聚合物,即 PVP 和 HPMC-AS 之间的药物-聚合物相互作用。在非水状态下,根据药物-聚合物 Flory-Huggins 相互作用参数,溶液 NMR 和 FT-IR 结果表明,909 与 PVP 之间存在强的特异性相互作用,而 909 与 HPMC-AS 之间不存在相互作用。在 95%相对湿度下长时间暴露于水分后,909/PVP 分子间相互作用不再存在,而 909 与 HPMC-AS 之间发生并持续存在疏水性相互作用。在 909 的水超饱和研究中,共溶的 PVP 显著优于预溶的 PVP,能够维持 909 的超饱和状态。我们假设共溶的 PVP 与 909 形成特异性相互作用,因此在水介质中相互作用破坏之前,能够延长 909 的超饱和状态,而预溶的 PVP 与水形成氢键,因此不再能够与 909 形成特异性相互作用以延长其超饱和状态。相比之下,HPMC-AS 通过疏水相互作用有效地介导 909 的超饱和状态,这种相互作用在水环境中变得明显,并且与 HPMC-AS 的添加方式无关。动态光散射分析支持了这一假设,其中发现纳米级药物/聚合物聚集体的形成与 909 的超饱和状态相关。总之,我们得出结论,聚合物介导的药物超饱和状态受在水环境中持续存在的药物-聚合物相互作用控制。因此,药物-聚合物相互作用的物理性质以及药物和聚合物的溶解动力学对于实现最佳 ASD 配方设计都至关重要。